肺动脉高压的评估与分类
Evaluation and classification of pulmonary arterial hypertension.
作者信息
Sahay Sandeep
机构信息
Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, Institute of Academic Medicine, Houston Methodist Hospital, Houston, TX, USA.
出版信息
J Thorac Dis. 2019 Sep;11(Suppl 14):S1789-S1799. doi: 10.21037/jtd.2019.08.54.
Abstract
In early 2019, the 6th World Symposium on Pulmonary Hypertension (WSPH) released an updated document highlighting the advances in the last five years. During the quinquennial event many experts worked together to suggest new changes in the disease diagnosis and management. Since inception of the WSPH in 1973, this is the first time when the hemodynamic definition of pulmonary hypertension (PH) has been updated. These proceedings have re-defined the different hemodynamic types of PH that occur with the left heart disease along with introduction to the genetic testing as part of pulmonary arterial hypertension (PAH) evaluation. Objective of this review is to highlight the evaluation and diagnosis of PAH based on the proceedings of the 6th WSPH. Accurate early diagnosis and subsequent management of PH is necessary, as despite of treatment advances, survival remains suboptimal.
摘要
2019年初，第六届世界肺动脉高压研讨会（WSPH）发布了一份更新文件，着重介绍了过去五年取得的进展。在这一五年一度的活动期间，众多专家共同努力，对疾病的诊断和管理提出了新的变化建议。自1973年WSPH成立以来，这是首次对肺动脉高压（PH）的血流动力学定义进行更新。这些会议重新定义了与左心疾病相关的不同血流动力学类型的PH，并引入了基因检测作为肺动脉高压（PAH）评估的一部分。本综述的目的是根据第六届WSPH的会议内容，着重介绍PAH的评估和诊断。尽管治疗取得了进展，但PH的生存情况仍不尽人意，因此准确的早期诊断和后续管理至关重要。
相似文献
1
Evaluation and classification of pulmonary arterial hypertension.
J Thorac Dis. 2019 Sep;11(Suppl 14):S1789-S1799. doi: 10.21037/jtd.2019.08.54.
2
The 6th World Symposium on Pulmonary Hypertension: what's old is new.
F1000Res. 2019 Jun 19;8. doi: 10.12688/f1000research.18811.1. eCollection 2019.
3
Update from the World Symposium on Pulmonary Hypertension 2018: does the new hemodynamic definition of pediatric pulmonary hypertension have an impact on treatment strategies?
Cardiovasc Diagn Ther. 2021 Aug;11(4):1048-1051. doi: 10.21037/cdt-20-412.
4
Haemodynamic definitions and updated clinical classification of pulmonary hypertension.
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
5
Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium.
Pulm Ther. 2020 Jun;6(1):9-22. doi: 10.1007/s41030-019-00105-5. Epub 2019 Nov 29.
6
How did the updated hemodynamic definitions affect the frequency of pulmonary hypertension in patients with systemic sclerosis?
Anatol J Cardiol. 2021 Jan;25(1):30-35. doi: 10.14744/AnatolJCardiol.2020.46625.
7
Pulmonary Hypertension in 2021: Part I-Definition, Classification, Pathophysiology, and Presentation.
J Cardiothorac Vasc Anesth. 2022 Jun;36(6):1552-1564. doi: 10.1053/j.jvca.2021.06.036. Epub 2021 Jul 8.
9
The impact of the new World Symposium on Pulmonary Hypertension definition of pulmonary hypertension on the prevalence of pre-capillary pulmonary hypertension.
Turk Kardiyol Dern Ars. 2019 Oct;47(7):594-598. doi: 10.5543/tkda.2019.80027.
10
The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease.
Diagnostics (Basel). 2021 Feb 15;11(2):311. doi: 10.3390/diagnostics11020311.
引用本文的文献
1
Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review.
Pharmacoeconomics. 2025 Apr 17. doi: 10.1007/s40273-025-01492-1.
2
Pulmonary hypertension and insulin resistance: a mechanistic overview.
Front Endocrinol (Lausanne). 2024 Jan 4;14:1283233. doi: 10.3389/fendo.2023.1283233. eCollection 2023.
3
PULMOEAST: A Comprehensive Analysis of Pulmonary Hypertension in Eastern India.
Cureus. 2023 Dec 23;15(12):e50996. doi: 10.7759/cureus.50996. eCollection 2023 Dec.
4
Kids Mod PAH trial: A multicenter trial comparing mono- versus duo-therapy for initial treatment of pediatric pulmonary hypertension.
Pulm Circ. 2023 Oct 31;13(4):e12305. doi: 10.1002/pul2.12305. eCollection 2023 Oct.
5
Catheterization of Pulmonary and Carotid Arteries for Concurrent Measurement of Mean Pulmonary and Systemic Arterial Pressure in Rat Models of Pulmonary Arterial Hypertension.
Bio Protoc. 2023 Aug 20;13(16):e4737. doi: 10.21769/BioProtoc.4737.
6
Optical Coherence Tomography Angiography Is a Useful Tool for Distinguishing Primary Raynaud's Phenomenon from Systemic Sclerosis and/or Very Early Disease of Systemic Sclerosis.
Diagnostics (Basel). 2023 Aug 5;13(15):2607. doi: 10.3390/diagnostics13152607.
7
Identification of Potential Biomarkers for Group I Pulmonary Hypertension Based on Machine Learning and Bioinformatics Analysis.
Int J Mol Sci. 2023 Apr 28;24(9):8050. doi: 10.3390/ijms24098050.
8
Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient.
J Pediatr Pharmacol Ther. 2023;28(1):102-107. doi: 10.5863/1551-6776-28.1.102. Epub 2023 Feb 3.
9
Real-World Safety and Clinical Outcomes of Macitentan in Asian Patients with Pulmonary Arterial Hypertension: A Prospective Multicenter Study.
Drugs Real World Outcomes. 2023 Mar;10(1):41-49. doi: 10.1007/s40801-022-00330-6. Epub 2022 Nov 3.
10
Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension.
Molecules. 2022 Jun 9;27(12):3724. doi: 10.3390/molecules27123724.
本文引用的文献
1
An overview of the 6th World Symposium on Pulmonary Hypertension.
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.02148-2018. Print 2019 Jan.
2
Pulmonary hypertension in chronic lung disease and hypoxia.
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01914-2018. Print 2019 Jan.
3
Genetics and genomics of pulmonary arterial hypertension.
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01899-2018. Print 2019 Jan.
4
Diagnosis of pulmonary hypertension.
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01904-2018. Print 2019 Jan.
5
Haemodynamic definitions and updated clinical classification of pulmonary hypertension.
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
6
TGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension.
Drug Discov Today. 2019 Mar;24(3):703-716. doi: 10.1016/j.drudis.2018.12.001. Epub 2018 Dec 7.
7
Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults.
Circ Genom Precis Med. 2018 Apr;11(4):e001887. doi: 10.1161/CIRCGEN.117.001887.
8
Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.
Eur Respir J. 2018 Apr 4;51(4). doi: 10.1183/13993003.01197-2017. Print 2018 Apr.
9
Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.
JAMA Cardiol. 2018 Apr 1;3(4):298-306. doi: 10.1001/jamacardio.2018.0128.
10
Does Late Gadolinium Enhancement still have Value? Right Ventricular Internal Mechanical Work, E/E and Late Gadolinium Enhancement as Prognostic Markers in Patients with Advanced Pulmonary Hypertension via Cardiac MRI.
Cardiol Res Cardiovasc Med. 2017;2017(1). Epub 2017 Jan 11.
Zotero 插件